Cowen And Company, LLC Protagonist Therapeutics, Inc Transaction History
Cowen And Company, LLC
- $3.88 Billion
- Q3 2024
A detailed history of Cowen And Company, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Cowen And Company, LLC holds 340,974 shares of PTGX stock, worth $14.8 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
340,974
Previous 1,182,268
71.16%
Holding current value
$14.8 Million
Previous $41 Million
62.59%
% of portfolio
0.39%
Previous 1.05%
Shares
7 transactions
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.4MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$254 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$249 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$235 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$182 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$138 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.12B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...